Approved TherapeuticAugust 5, 2026
Semaglutide
Ozempic
Type 2 diabetes · Chronic weight management
Tier 1Approved
SafetyKnown but Manageable Risks
- Sponsor
- Novo Nordisk
- Phase
- Approved
Loading Daily Peptide Guide…
Ranked by clinical relevance, scientific importance and breadth of impact—not by commercial attention.
Ozempic
Type 2 diabetes · Chronic weight management
Mounjaro
Type 2 diabetes · Chronic weight management
Victoza
Type 2 diabetes · Chronic weight management
Trulicity
Type 2 diabetes · Cardiovascular risk reduction
Forteo
Osteoporosis · High fracture risk
Tymlos
Osteoporosis · High fracture risk
Sandostatin
Acromegaly · Carcinoid syndrome
Somatuline Depot
Acromegaly · Neuroendocrine tumors
Leuprorelin
Prostate cancer · Endometriosis
Gattex
Short bowel syndrome
Linzess
Irritable bowel syndrome with constipation · Chronic idiopathic constipation
Trulance
Chronic idiopathic constipation · IBS-C
Prialt
Severe chronic pain
Recombinant human growth hormone
Growth-hormone deficiency · Selected growth disorders
Increlex
Severe primary IGF-1 deficiency
Egrifta
Excess abdominal fat in adults with HIV-associated lipodystrophy
Lutathera
Gastroenteropancreatic neuroendocrine tumors · Theranostics
LY3437943
Obesity · Type 2 diabetes
Cagrilintide + semaglutide
Obesity · Type 2 diabetes
NN9833
Obesity · Type 2 diabetes
BI 456906
Obesity · MASH
MariTide
Obesity · Type 2 diabetes
VANQUISH asset
Obesity · Type 2 diabetes
ALT-801
Obesity · MASH
Zenagamtide
Obesity · Type 2 diabetes
LY3841136
Obesity
Experimental metabolic peptide
Obesity · Metabolic disease
ZP8396
Obesity
IBI362
Obesity · Type 2 diabetes
SS-31
Barth syndrome · Mitochondrial disease research
Cibinetide
Small-fiber neuropathy · Inflammatory conditions
BYM338
Body-composition research · Muscle-wasting research
ActRII pathway class
Muscle-wasting research · Neuromuscular disease research
GHS pathway class
Catabolic-disease research · Appetite research
APJ agonist programs
Metabolic research · Cardiovascular research
GHSR agonist programs
Cachexia research · Appetite-loss research
GLP-1 multi-agonist class
Obesity · Weight management research
Body protection compound 157
Recovery claims · Gastrointestinal claims
Thymosin beta-4 fragment
Recovery claims · Wound-healing claims
Mitochondrial open reading frame of 12S rRNA-c
Longevity claims · Exercise claims
HN peptide
Neuroprotection research · Longevity claims
Epithalon
Longevity claims · Sleep claims
CJC-1295 DAC
Growth hormone claims · Body-composition claims
Ipamorelin acetate
Growth hormone claims · Body-composition claims
GHRH(1-29)
Growth hormone claims · Body-composition claims
Examorelin
Growth hormone claims · Body-composition claims
Pralmorelin
Growth hormone claims · Body-composition claims
Growth hormone-releasing peptide 6
Growth hormone claims · Appetite claims
Lys-Pro-Val
Inflammation claims · Skin and gut claims
Thymalfasin
Immune modulation · Infectious disease research